Update shared on20 Aug 2025
Fair value Increased 19%The notable rise in Hansa Biopharma’s consensus analyst price target to SEK90.00 is primarily driven by a substantial increase in its anticipated future P/E multiple, reflecting higher market growth expectations.
What's in the News
- Hansa Biopharma announced topline results from three DMD patients treated with imlifidase prior to ELEVIDYS gene therapy, showing rapid IgG reduction and enabled gene therapy, but with lower micro-dystrophin expression than other trials; next steps to be discussed with Sarepta.
- Five-year pooled analysis of imlifidase-enabled kidney transplants showed patient survival at 90% and graft survival at 82%, with sustained kidney function in long-term follow-up.
- Completed a follow-on equity offering, raising SEK 232.1 million by issuing 10,550,000 common shares at SEK 22 each via a direct listing.
- Common shares subject to a 90-day lock-up period, restricting sales by board and executive management following the equity offering.
- Plans announced to restructure the organization, reducing workforce by approximately 20% and targeting annual savings of SEK 40-50 million, subject to union negotiations.
Valuation Changes
Summary of Valuation Changes for Hansa Biopharma
- The Consensus Analyst Price Target has significantly risen from SEK75.50 to SEK90.00.
- The Future P/E for Hansa Biopharma has significantly risen from 24.19x to 28.82x.
- The Discount Rate for Hansa Biopharma remained effectively unchanged, moving only marginally from 5.32% to 5.28%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.